Meet the One Million Strong: Jo-Ann C. from Ontario,Canada

Be a part of One Million Strong and tell us how colorectal cancer has impacted your life! Share your story now!  MEET JO-ANN Jo-Ann Cluney, Survivor Pickering, Ontario, Canada JO-ANN’S STORY I was diagnosed with Stage IIIB Colorectal Cancer in November of 2011.  I had a colon resection within two weeks of diagnoses and started chemo and…  Read More

Meet the One Million Strong – Marcia M from West Virginia

Be a part of One Million Strong and tell us how colorectal cancer has impacted your life! Share your story now!  MEET MARCIA Marcia Mullins, Survivor Huntington, WV MARCIA’S STORY Despite Katie Couric’s warning, when I turned 50 I declined to have a colonoscopy, I didn’t think I was at risk. When I had symptoms at 57, I…  Read More

New Trial Looks to Reduce Recurrence and Neuropathy for Stage III Patients

If you are diagnosed with stage III colon cancer, you will probably receive about six months of treatment with FOLFOX after surgery. Research shows that this treatment regimen helps prevent recurrence for some – but not all – patients with stage III colon cancer.  A clinical trial has been launched to answer two questions about this…  Read More

Chemo Delay After Surgery Reduces Survival Rates

A paper presented at the recent 2011 Gastrointestinal Cancers Symposium conference reported important evidence that, for colorectal cancer patients getting chemotherapy after surgery, the sooner the better. For people diagnosed with stage III colon cancer, stage II rectal cancer, or stage II colon cancer showing certain high-risk features, researchers found that each four-week delay in starting chemotherapy…  Read More

Leading GI Cancer Researcher Updates Patients

Last night, Dr. Edith Mitchell of Thomas Jefferson University Kimmel Cancer Center in Philadelphia, PA, updated colorectal cancer patients on the latest research and treatment news in an online webinar. Dr. Mitchell highlighted the most important news for colon and rectal cancer patients to come from the 2011 Gastrointestinal Cancers Symposium held in San Francisco last…  Read More

No Benefit Adding Cetuximab to Chemo for Stage III Colon Cancer

Adding Erbitux® (cetuximab) to standard chemotherapy for stage III colon cancer didn’t improve patient outcomes and added more side effects. All of the patients in the NO147 trial had cancer that had spread to their lymph nodes and had surgery before beginning chemotherapy. They had normal or wild-type KRAS genes in their tumors.They were randomly assigned…  Read More